posted on 2023-05-22, 14:20authored byRitu Chaudhary, Robbert J.C. Slebos, Leenil C. Noel, Feifei Song, Maria I. Poole, Dirk S. Hoening, Juan C. Hernandez-Prera, Jose R. Conejo-Garcia, Jose A. Guevara-Patino, Xuefeng Wang, Mengyu Xie, Aik Choon Tan, Christine H. Chung
Supplementary Table S5. Immune profile of the primary and recurrent tumors in Moffitt HNSCC cohort
Funding
HHS | NIH | National Institute of Dental and Craniofacial Research (NIDCR)
HHS | NIH | National Cancer Institute (NCI)
James and Esther King Biomedical Research Grant
History
ARTICLE ABSTRACT
While the hypoxic and immunosuppressive TME of HNSCC has been well described, comprehensive evaluation of the immune cell components and signaling pathways contributing to immunotherapy resistance has been poorly characterized. We further identified additional molecular determinants and potential therapeutic targets of the hypoxic TME to fully leverage currently available targeted therapies that can be administered with immunotherapy.